Talphera, Inc. announced that it expects to receive $16 million in funding from Nantahala Capital Management, LLC, Rosalind Advisors, Inc.
January 16, 2024
Share
Talphera, Inc. announced that it ahs entered into Securities Purchase Agreements with certain institutional investors to issue pre-funded warrants to the Purchasers in a two-tranche private placement to purchase shares of the company?s common stock, par value $0.001 per share at a purchase price of $0.769 per share and an exercise price of $0.001 per share for the gross proceeds of $16,000,000 on January 17, 2024. The transaction will include participation from returning investors Nantahala Capital Management, LLC and Rosalind Advisors, Inc. The securities are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, and have not been registered under the Securities Act, or applicable state securities laws. The company will also issue an additional $2 million stock trade at a price of at least $0.92 per share for 5 days after the announcement of the NEPHRO registration trial data.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
TALPHERA, INC. 
